Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients

Journal of Clinical Psychiatry

Volumn 59, Issue 10, 1998, Pages 502-508

  Thase, Michael E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; PLACEBO; VENLAFAXINE;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAM; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL RATE;

EID: 0031755709     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n1002     Document Type: Article

References (33)

1. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-294
2. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995;56:574-579
3. Thase ME, for the Venlafaxine XR 209 Study Group. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 1997;58:393-398
4. Cunningham LA, for the Venlafaxine XR 208 Study Group. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 1997;9(3): 157-164
5. Thase ME, Howland RH. Biological processes in depression: an updated review and integration. In: Beckman EE, Leber WR, eds. Handbook of Depression. 2nd ed. New York, NY: Guilford; 1995:213-279
6. Delgado PL, Price LH, Heninger GR, et al. Neurochemistry. In: Paykel ES, ed. Handbook of Affective Disorders. 2nd ed. New York, NY: Guilford; 1992:219-253
7. Nelson JC. Are the SSRIs really better tolerated than the TCAs for treatment of major depression? Psychiatr Ann 1994;24:628-631
8. Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991;325:633-642
9. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-1739
10. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-138
11. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
12. Pande AC, Sayler ME. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 1993;8:243-245
13. Fabre LF, Putman HP III. An ascending single-dose tolerance study of WY-45,030, a bicyclic antidepressant, in healthy men. Curr Ther Res 1987;42:901-909
14. Goldberg HL, Finnerty R. An open-label, variable-dose study of WY-45,030 (venlafaxine) in depressed outpatients. Psychopharmacol Bull 1988;24:198-199
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
17. Reeves RA. Does this patient have hypertension? how to measure blood pressure. JAMA 1995;273:1211-1218
18. White WB, Lund-Johansen P, Omvik P. Assessment of four ambulatory blood pressure monitors and measurements by clinicians versus intraarterial blood pressure at rest and during exercise. Am J Cardiol 1990;65: 60-66
19. Robertson JIS. Guidelines for the treatment of hypertension: a critical review. Cardiovasc Drugs Ther 1994;8:665-672
20. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-183
21. Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data? reply to comments. Neuropsychopharmacology 1992;6: 61-63
22. Gibbons RD, Hedeker D. Application of random effects probit regression models. J Consult Clin Psychol 1994;62:285-296
23. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman & Hall; 1984
24. Glassman AH, Bigger JTJ, Giardina EV, et al. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1979;1:468-472
25. Glassman AH, Roose SP, Giardina E-GV, et al. Cardiovascular effects of tricyclic antidepressants. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987: 1437-1442
26. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219
27. Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991; 148:512-516
28. Thase ME. Antidepressant options: venlafaxine in perspective. J Clin Psychopharmacol 1996;16(suppl 2):10S-20S
29. Clerc GE, Ruimy P, Verdeau-Paillés J, on behalf of the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143
30. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71
31. Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992;268:3441-3445
32. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995;310:221-223
33. Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997;54:1009-1015